Gilead U.S. Investment to Create $43 Billion in Value to U.S. Economy

Back

Gilead to invest $32 billion in U.S. manufacturing and R&D through 2030 and create more than 3,000 direct and indirect jobs by 2028

Foster City, Calif., May 7, 2025 – Gilead Sciences is committed to advancing world-class science and driving innovation — with the United States at the heart of our operations. Today, our U.S. R&D and manufacturing footprint is our largest globally. Our U.S. R&D and manufacturing investments in the U.S. will create $43 billion in value to the U.S. economy over the next five years through direct capital investment and job creation. This comprehensive investment further bolsters Gilead’s domestic research, development, and manufacturing capabilities while advancing the company’s mission to discover and develop life-changing medicines.

Details of the overall investment include a newly announced $11 billion in capital and operational investments in the U.S. to supplement an already planned spend of $21 billion in U.S. manufacturing and R&D through 2030. Together, this is estimated to generate an additional $11 billion in U.S. economic impact.

This next phase of investment will support the building three new, state-of-the-art facilities, upgrading three existing sites to expand U.S. manufacturing and R&D capabilities, and investing in new technology and advanced engineering initiatives. Moreover, the additional $11 billion will cover:

$4 billion allocated to capital projects, including labs and equipment.
$5 billion dedicated to technology, operations, and R&D site activities.
$2 billion invested in digital and advanced engineering initiatives
Creation of approximately 800 new direct jobs and support more than 2,200 indirect jobs by 2028.

These current investments further build on Gilead’s strong history of U.S. investment with $15 billion over the last 10 years and reinforces the company’s role as a key contributor to the U.S. biopharmaceutical industry and a vital partner in driving scientific innovation and solutions for our patients.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences